The target of NLX-101, 5-HT1A receptors, are the predominant inhibitory 5-HT receptor subtype, decreasing cAMP production via activation of Gαi proteins [72], a process that is dysregulated in FXS [73]. This evidence concerns the gene HTR1A and fragile X syndrome.